- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Study: Fibromyalgia patients taking pregabalin see improvement in sleep, daily pain
Fibromyalgia patients taking pregabalin had significant improvements in sleep and decreased daily pain, according to a new study published in the April 2012 issue of Arthritis Care & Research.
Fibromyalgia patients taking pregabalin had significant improvements in sleep and decreased daily pain, according to a new study.
Published in the April 2012 issue of Arthritis Care & Research, the study was led by Thomas Roth, PhD, of the Sleep Disorders and Research Center, the Henry Ford Health System in Detroit.
Researchers conducted a randomized, double-blind, placebo-controlled crossover study using polysomonographic (PSG) measures of sleep. Fibromyalgia patients taking 300 mg to 450 mg of pregabalin per day showed a reduction in PSG-determined wake versus sleep onset of -19.2 minutes versus placebo at -26.7 minutes. Patients’ pain score also improved with pregabalin by -.52.
The researchers also found modest but significant correlations between PSG sleep assessments and pain and sleep quality. “Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep,” Roth wrote in the study.
In addition, pregabalin was generally well tolerated, although 30.4% of patients taking pregabalin reported dizziness, 20.5% experienced somnolence, and 8.9% of fibromyalgia patients had headaches with pregabalin.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
